Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 3/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | TEK | Q02763 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1785444 | 1.00 | MERTK (0.33) | MERTKCYP11B1CYP11B2AURKATNK2 | |
| SCHEMBL1786511 | 1.00 | MERTK (0.33) | MERTKCYP11B1CYP11B2AURKATNK2 | |
| SCHEMBL3125008 | 0.91 | MERTK (0.37) | MERTKAURKATNK2FFAR4LCK | |
| SCHEMBL1785336 | 0.91 | MERTK (0.37) | MERTKAURKATNK2FFAR4LCK | |
| SCHEMBL12607233 | 0.91 | AURKA (0.40) | MERTKAURKATNK2LCKEGFR | |
| SCHEMBL12607234 | 0.91 | AURKA (0.40) | MERTKAURKATNK2LCKEGFR | |
| SCHEMBL12607248 | 0.88 | AURKA (0.43) | MERTKAURKATNK2LCKEGFR | |
| SCHEMBL14467485 | 0.88 | AURKA (0.43) | MERTKAURKATNK2LCKEGFR | |
| SCHEMBL14467153 | 0.88 | AURKA (0.43) | MERTKAURKATNK2LCKEGFR | |
| SCHEMBL12607257 | 0.88 | AURKA (0.43) | MERTKAURKATNK2LCKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324222-B2 | Cyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | DPYD, TK2, TPMT | MERTK 974/4885CYP11B1 106/4885CYP11B2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.